Pain Therapeutics Touts Naltrexone Safety Profile Over Marketed IBS Drugs
Executive Summary
Pain Therapeutics believes its low-dose oral naltrexone will offer a more positive risk-benefit profile and broader efficacy compared to marketed irritable bowel syndrome therapies
You may also be interested in...
Purdue Withdraws Palladone; FDA Evaluating Other Extended-Release Opiates
FDA is evaluating the potential for an alcohol interaction with other sustained-release opiates following the withdrawal of Purdue Pharma's Palladone due to the potential for serious alcohol-related adverse events
Purdue Withdraws Palladone; FDA Evaluating Other Extended-Release Opiates
FDA is evaluating the potential for an alcohol interaction with other sustained-release opiates following the withdrawal of Purdue Pharma's Palladone due to the potential for serious alcohol-related adverse events
Remoxy Time-Release Oxycodone Phase III Trial Planned For Year-End
Pain Therapeutics plans to initiate a Phase III trial for Remoxy, its time-release oxycodone, around year-end